Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Moderna to complete US mRNA manufacturing network with $140 million investment - 2Lebanese Shi’a party Amal competing, coordinating with Hezbollah, experts tell ‘Post’
- 3Mechanical Sidekick d: A Survey of \Elements and Execution d\ Cell phone
- 4Tzrifin base exhibition reveals Hamas and Hezbollah arms, showing structure behind attacks
- 5I visited the largest collection of public telescopes in the US in Oregon's high desert, and the dark skies blew me away
- ‘Wicked: For Good’ streaming release — How to watch the sequel starring Ariana Grande and Cynthia Erivo
- The 15 Most Rousing TED Chats on Self-awareness
- Israel strikes south Lebanon after first direct talks in decades
- US EPA will reassess safety of herbicide paraquat, says its chief
- Rights group: At least 2,500 deaths during protest crackdown in Iran
- Hezbollah uses ambulances, paramedic uniforms, as disguise for terrorist activity, IDF says
- James Webb Space telescope spots 'big red dot' in the ancient universe: A ravenous supermassive black hole named 'BiRD'
- Freed whale gets stranded again off German coast
- Fabricated statement about Malaysian national exam top scorers stokes racial sentiment
